Head-To-Head Survey: Caribou Biosciences (NASDAQ:CRBU) and Altimmune (NASDAQ:ALT)

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Caribou Biosciences and Altimmune, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences 1 4 1 1 2.29
Altimmune 1 1 8 0 2.70

Caribou Biosciences currently has a consensus price target of $4.50, suggesting a potential upside of 1,143.44%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 771.33%. Given Caribou Biosciences’ higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Altimmune.

Insider and Institutional Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 78.0% of Altimmune shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Caribou Biosciences and Altimmune’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caribou Biosciences -1,085.00% -102.74% -69.45%
Altimmune N/A -31.84% -27.40%

Earnings and Valuation

This table compares Caribou Biosciences and Altimmune”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Caribou Biosciences $11.16 million 3.50 -$148.12 million ($1.03) -0.35
Altimmune $40,000.00 7,999.64 -$88.09 million ($0.78) -2.11

Altimmune has lower revenue, but higher earnings than Caribou Biosciences. Altimmune is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Caribou Biosciences has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.

Summary

Altimmune beats Caribou Biosciences on 9 of the 15 factors compared between the two stocks.

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.

About Altimmune

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.